TG Therapeutics Shows New Preliminary Data

Pharmaceutical Investing

TG Therapeutics revealed preliminary results from an ongoing Phase 2 study of TG-1101 treating patients with relapsing forms of multiple sclerosis.

TG Therapeutics (NASDAQ:TGTX) will reveal new preliminary results from an ongoing Phase 2 study of TG-1101 treating patients with relapsing forms of multiple sclerosis.
As quoted in the press release:

The data is being presented today at the 69th American Academy of Neurology (AAN) annual meeting, taking place in Boston, MA. The poster is available for viewing during poster session 6, from 8:30 AM – 5:30 PM ET.

The poster, entitled “Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion“ (Abstract Number: 3113; Poster number 6.348), includes data from 24 patients with RMS treated with TG-1101.  Three dosing cohorts of up to 8 patients each were evaluated to assess the safety and tolerability of TG-1101 at accelerated infusion times.

Click here to read the full press release.

Source: globenewswire.com

The Conversation (0)
×